A Study Of Acr-368 In Ovarian Carcinoma, Endometrial Adenocarcinoma, And Urothelial Carcinoma
Posted Date: Apr 26, 2024
- Investigator: Caroline Billingsley
- Specialties: Cancer, Gynecologic Oncology, Ovarian Cancer
- Type of Study: Drug
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.
Criteria:
Null
Keywords:
Platinum-Resistant Ovarian Cancer, Endometrial Cancer, Urothelial Carcinoma
For More Information:
Jessica Mullins
NULL
cancer@uchealth.com